ArticleActa cirurgica brasileira2026
Study on the effect of Portulaca oleracea L. extract on chronic ulcerative colitis in rats induced by allogeneic antigen and acetic acid.
Article in Acta cirurgica brasileira, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effect and mechanism of Portulaca oleracea L. (POL) extract on acetic acid and alloantigen-induced chronic ulcerative colitis in rats.
methodsUlcerative colitis was induced in rats by sensitization with rabbit colon antigen and acetic acid. Rats received oral sulfasalazine, intestine-quieting tablet, or POL (high, medium, or low dose) for 14 days. Disease activity index (DAI), colonic mucosal damage index (CMDI), and histological score (HS) were assessed. Serum levels of interleukin (IL)-4, IL-8, IL-17, C-reactive protein (CRP), immunoglobulin G (IgG), and interferon-γ (IFN-γ); colonic levels of myeloperoxidase (MPO), epidermal growth factor (EGF), and tumor necrosis factor (TNF)-α; serum hemolysin (by immunoturbidimetry); splenic T lymphocyte subsets (by flow cytometry); and serum IgG, IgM, IgA, C3, and C4 were measured.
resultsCompared with the model group, POL significantly reduced DAI, CMDI, and HS scores in a dose-dependent manner-most markedly in the high-dose group (p < 0.01). POL also significantly decreased serum IL-8, IL-17, CRP, IFN-γ, and IgG, and colonic TNF-α and MPO (p < 0.05 or p < 0.01), while increasing serum IL-4 and colonic EGF (p < 0.01). All POL dosage groups significantly increased hemolysin, IgM, and CD4+CD25+/CD4+ levels in rats (p < 0.05 or p < 0.01), while decreasing serum IgG, IgA, complement C3/C4, CD4+/CD8+, and IL-17+ CD4+ (p < 0.05 or p < 0.01).
conclusionThe POL extract exerts therapeutic effects in chronic ulcerative colitis rats, likely by downregulating pro-inflammatory mediators-including IL-8, IL-17, CRP, IFN-γ, TNF-α, and MPO-, as well as serum IgG, IgA, C3/C4, CD4+/CD8+, and IL-17+ CD4+; and by upregulating anti-inflammatory/repair factors-including IL-4, EGF, lysozyme, IgM, and CD4+CD25+/CD4+. These findings support the clinical potential of POL for ulcerative colitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.